Pancreatic cancer has the highest mortality rate among major cancers and is currently the third leading cause of cancer-related deaths in the United States, following lung and colon cancer. It is projected to become the second leading cause by 2030. (Source: Hirshberg Foundation). Pancreatic cancer may be treated with surgery if caught early, as well as with chemotherapy, radiation, or targeted therapies, but treatments that consistently improve survival are still limited. In the U.S., only about 10% of patients live for at least 5 years after being diagnosed with pancreatic cancer. Gemcitabine-based therapies, especially in combination with Abraxane, are the most widely used pancreatic cancer treatment category.
The stock we are bringing to your attention today is Actuate Therapeutics Inc. (ACTU), which is developing a drug for metastatic pancreatic cancer.
For comments and feedback: editorial@rttnews.com